New Frontiers with BCMA Targeting in the Treatment of Heavily Relapsed Multiple Myeloma - Baseline Assessment

Primary Audience:

This activity is intended to meet the educational needs of hematologists/ oncologists involved in the treatment of patients with RRMM.

The following questions are designed to assess your knowledge and practice of patients with relapsed refractory multiple myeloma.
Apply foundational understanding of the mechanism of action and target of BCMA therapies to patient discussions and clinical practice.
Use knowledge of the latest clinical data on BCMA therapies in RRMM, including key trials, efficacy insights, and side effect profiles in clinical decision making.
Use guideline recommendations and expert guidance for the use of MRD in response assessment and therapy management for RRMM.
Use practical approaches to patient discussion when considering utilizing BCMA targeted therapies for patients with RRMM.